Adrenoleukodystrophy in Adults: About a Case

1Si Ahmed Hakim, 1Ouardia Belarbi, 1Smail Daoudi, 1Ferroudja Miloudi, 1Massinissa Lounis 1Department of Neurology, Nedir Mohamed Teaching Hospital, Tizi Ouzou, Algeria Background: The goal is to think about leukodystrophy which can mimic a progressive picture of multiple sclerosis Material(s) and Method(s): We report the observation of a man with adreno-leukodystrophy whose neurological manifestations were late.…

MRI Findings in Late-Onset Multiple Sclerosis; a Systematic Review and Meta-Analysis

1Amirreza Naseri, 1Ehsan Nasiri, 2Mohammad Ali Sahraian, 3Sara Daneshvar, 3Mahnaz Talebi 1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; 2Sina MS Research Center, Sina hospital, and department of neurology, Tehran University of Medical Sciences,, Tehran, Iran; 3Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran Background: Multiple sclerosis (MS) commonly affects…

Chitinase-3 Like-Protein-1 in CSF: A Novel Biomarker for Progression in Multiple Sclerosis Patients

1Ahmed Dahshan, 1Christine Ragaie, 1Foraysa El-Sayed Mohammed Talaat 1Cairo University, Cairo, Egypt Background: Chitinase -3-Like protein-1 (CHI3L1) is a glycoside secreted by monocytes, microglia, and activated astrocytes. Its distribution in inflammatory lesions suggests that it might be an important component of the astrocytic response to modulate CNS inflammation. CHI3L1 levels in CSF have been found…

COVID-19 in Multiple Sclerosis Patients in Dubai: Observational Study

1Mona Thakre, 2Jihad Inshasi 1Al Zahra Hospital Dubai, Dubai, United Arab Emirates; 2Rashid Dubai, Dubai, United Arab Emirates Background: Covid 19 pandemic came with its own challenges of novelty, lack of information uncertainty of treatment and its effect on chronic autoimmune diseases like Multiple sclerosis. The outcome of covid 19 with immunosuppressive and immunomodulatory treatment…

Humoral Immune Response to SARS-CoV-2 Vaccination in MS Patients

1Celia Oreja-Guevara, 1Judit Díaz-Díaz, 1Elda Alba Suárez, 1Irene Gómez-Estévez, 1Johnny Quezada Sánchez, 1Cristina Bullón-Sánchez, 1Matilde Castro-Hernández, 1Eduardo Martinez-Pérez, 1Silvia O´Connor Pérez, 1Elvira Baos Muñoz 1Hospital Clínico San Carlos, Madrid, Spain Objective(s): The aim of this study was to study the humoral immune response to SARS-CoV-2 following vaccination in MS patients. Material(s) and Method(s): We performed…

Association of COVID-19 with Disability Progression and Disease Exacerbation in People with Relapsing-Remitting Multiple Sclerosis: Evidence from a Year-Long Observational Study

1Nahad Sedaghat, 1Masoud Etemadifar, 1Hosein Nouri, 1Amir Parsa Abhari, 1Shiva Maleki, 1Alireza Amin, 2Mehri Salari 1Isfahan University of Medical Sciences, Isfahan, Iran; 2Shahid Beheshti University of Medical Sciences, Tehran, Iran Objective(s): Neurological complications of COVID-19 have raised serious concerns among the experts, and hence, many mechanisms have been proposed to explain it. We sought to…

MicroRNA-484 and Apoptotic Protease Activating Factor-1 Gene in Relapsing Remitting Multiple Sclerosis: the Possible Interplay

1,2Alaa Elmazny, 3Dalia Abdel Wahab Mohamed, 2Heba Selim, 2Ali Genena, 3Mai Mohamed Nabil, 2Nevin Mohieldin, 2Hatem Shehata 1Arabian Gulf University, Manama, Bahrain; 2Cairo University, Cairo, Egypt; 3Ain Shams University, Cairo, Egypt Background: Emerging evidence suggests that dysregulated apoptosis might be implicated in the pathogenesis of multiple sclerosis (MS). In this study we evaluated the expression…

The Effect of Disease Modifying Drugs of Multiple Sclerosis on the Effectiveness of BBIBP-CorV COVID-19 Vaccine

1Mehran Ghaffari, 1Nahid Beladimoghadam, 1Seyed Hossein Aghamiri, 1Mehrdad Haghighi, 1Abdolreza Javadi, 2Mohammadali Nahayati 1Imam Hossein Medical and Educational Center, Tehran, Iran; 2Ghaem Medical and Educational Center, Mashhad, Iran Background: Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for curbing the pandemic. There are many concerns about the effectiveness of vaccination in patients…

First Study in Iraq About (HLA)-Drb1 * 15:01 as a Genetic Risk Factor for MS Initiation

1Alaa Hassan Khaliel, 2Ahmed Abdul- Hassan Abbas, 3Anmar Oday Hatem 1Ministry of Health, Baghdad, Iraq; 2College of Medicine, Al-Nahrain University, Baghdad, Iraq; 3Baghdad Teaching Hospital, Baghdad, Iraq Background: To assess the genotypes of (HLA)-DRB1 * 15:01 as genetic risk factor for MS development in samples of Iraqi MS patients. Material(s) and Method(s): This Case control…